Payment overview · 2025
General Payments
$1,692.95
79 reported records · 19 companies
Healthcare provider profile · identity verified
Fadi Oska, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STERLING HEIGHTS, MI · NPI 1205856432
Verified facts
What the public records show
CMS Open Payments records show Fadi Oska, M.D. received $1,692.95 in general payments during 2025 across 79 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $372.04 | 22.0% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $329.02 | 19.4% | 16 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $176.91 | 10.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $167.82 | 9.9% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $90.66 | 5.4% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $69.21 | 4.1% | 4 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $66.91 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.54 | 3.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.89 | 2.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.66 | 2.7% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $44.50 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.63 | 2.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $36.22 | 2.1% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $32.58 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.40 | 1.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.75 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.47 | 1.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.66 | 1.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.08 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,692.95 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $202.53 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $176.91 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $169.14 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.71 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $101.05 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $96.38 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $90.66 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $69.21 | 4 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $66.91 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $66.91 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $66.91 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.77 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.77 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.54 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.80 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.50 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.85 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.66 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.66 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.19 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $44.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.63 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $36.22 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $32.58 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.27 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 250 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 220 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
220 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
250 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 587 | 174 |
| Omeprazole | Omeprazole | 528 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 445 | 138 |
| Metoprolol Succinate | Metoprolol Succinate | 411 | 137 |
| Metformin Hcl | Metformin Hcl | 330 | 98 |
| Losartan Potassium | Losartan Potassium | 309 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 296 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 90 |
| Simvastatin | Simvastatin | 289 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 283 | 94 |
| Furosemide | Furosemide | 279 | 90 |
| Alprazolam | Alprazolam | 272 | 74 |
| Gabapentin | Gabapentin | 255 | 63 |
| Eliquis | Apixaban | 250 | 65 |
| Ozempic | Semaglutide | 220 | 36 |
| Lisinopril | Lisinopril | 208 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 51 |
| Montelukast Sodium | Montelukast Sodium | 130 | 44 |
| Carvedilol | Carvedilol | 127 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 118 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 28 |
| Jardiance | Empagliflozin | 107 | 32 |
| Allopurinol | Allopurinol | 104 | 35 |
| Sertraline Hcl | Sertraline Hcl | 98 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 42 |
| Enalapril Maleate | Enalapril Maleate | 94 | 27 |
| Atenolol | Atenolol | 93 | 28 |
| Methylprednisolone | Methylprednisolone | 91 | 70 |
| Clonazepam | Clonazepam | 90 | 19 |
| Cephalexin | Cephalexin | 88 | 72 |
| Potassium Chloride | Potassium Chloride | 88 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 33 |
| Mounjaro | Tirzepatide | 84 | 17 |
| Pregabalin | Pregabalin | 84 | 22 |
| Tramadol Hcl | Tramadol Hcl | 83 | 32 |
| Spironolactone | Spironolactone | 81 | 26 |
| Celecoxib | Celecoxib | 76 | 34 |
| Glimepiride | Glimepiride | 76 | 23 |
| Prednisone | Prednisone | 76 | 43 |
| Famotidine | Famotidine | 72 | 27 |
| Azithromycin | Azithromycin | 69 | 58 |
| Finasteride | Finasteride | 66 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 18 |
| Ezetimibe | Ezetimibe | 62 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 21 |
| Januvia | Sitagliptin Phosphate | 60 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Cefuroxime | Cefuroxime Axetil | 56 | 47 |
| Chlorthalidone | Chlorthalidone | 54 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 18 |
| Xarelto | Rivaroxaban | 52 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 49 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 18 |
| Farxiga | Dapagliflozin Propanediol | 46 | 11 |
| Donepezil Hcl | Donepezil Hcl | 45 | 12 |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 13 |
| Diazepam | Diazepam | 42 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Trazodone Hcl | Trazodone Hcl | 41 | 13 |
| Clonidine Hcl | Clonidine Hcl | 39 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 20 |
| Mirtazapine | Mirtazapine | 38 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 16 |
| Trulicity | Dulaglutide | 38 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 15 |
| Minoxidil | Minoxidil | 35 | 14 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 12 |
| Meloxicam | Meloxicam | 33 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Methocarbamol | Methocarbamol | 32 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 17 |
| Hydrocortisone | Hydrocortisone | 31 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 21 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Temazepam | Temazepam | 25 | 11 |
| Valsartan | Valsartan | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | 12 |
| Amoxicillin | Amoxicillin | 23 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 17 |
| Fluconazole | Fluconazole | 20 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | 11 |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,692.95 · 79 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GLYCATE, INSPIRE, KRYSTEXXA, MOUNJARO, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, PROLIA, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, UBRELVY, UPTRAVI, VERQUVO, VOQUEZNA, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error